Peter Chiou Sees Potential In SemiLEDs (LEDS); Continued Interest in Mazor Robotics’ (MZOR) Renaissance System


Shares of SemiLEDs Corp. (Nasdaq:LEDS) soared more than 50% in the extended session Wednesday after the company disclosed in a regulatory filing ( FORM 8-K ) with the U.S. Securities and Exchange Commission (SEC) that Dr. Peter Chiou will acquire an approximately 19.6% stake (577,000 shares) in SemiLEDs at $5.00 per share.

According to the LED chips and components maker, Peter Chiou will be appointed – after the completion of the transaction – a member of its board of directors

LEDS stock closed at $3.30, up $0.49 (or +17.41%), with a total volume of 288,090 shares traded during the day, representing a large increase in activity versus its average volume (3m) of 31,600

SemiLEDs has 2.90M Shares Outstanding, Market Capitalization (intraday) of $9.57M and LEDS stock 52-week range is from $1.36 to $6.90 per share



Mazor Robotics Ltd. (Nasdaq:MZOR) shares climbed to touch a new 52-week high of $20.56 in intraday trading Wednesday as the company said that it received purchase orders for eleven Renaissance systems – its surgical guidance system for spine and brain surgery – during the second quarter

Mazor Robotics expects to report its second-quarter 2016 financial results next month

MZOR stock finished the regular session at $19.45, up $0.25 (or +1.30%).

Mazor Robotics, which develops and markets surgical guidance systems and complementary products, has 42.26M Shares Outstanding, Market Capitalization (intraday) of $440.95M and MZOR stock one-year range is now between $8.31 and $20.56 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at